|
|
SciBase reaches milestone with over 400,000 tests sold with Nevisense |
|
|
Interim report. |
|
|
New Study Positions Nevisense's EIS as a valuable and sensitive tool for assessing skin barrier impairment |
|
|
New Publication: US clinicians' real-world Nevisense experience improves melanoma detection |
|
|
SciBase receives approval by FDA for extended labelling in the US |
|
|
SciBase's Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma |
|
|
A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns |
|
|
Recalculation of warrants of series TO 2 following rights issue and updated last day of trading in BTA from the rights issue |
|
|
SciBase announces final outcome of the rights issue and the resolution on a set-off issue within the framework of the offer to repurchase outstanding warrants of series TO 2 |
|
|
Change of date for publication of the year-end report for the financial year 2025 |
